Clinical Trials Browser

Phase 1/2 × OTHER × dalpiciclib × Clear all

NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

Breast Neoplasms